20/20 Biolabs, Inc. (AIDX) Financials

20/20 Biolabs, Inc. (AIDX) reported diluted earnings per share of -$0.76 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

20/20 Biolabs, Inc. (AIDX) had EBITDA of -$3.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, 20/20 Biolabs, Inc. (AIDX) had $1.0M in cash and equivalents against $619K in long-term debt.

20/20 Biolabs, Inc. (AIDX) had a gross margin of 29.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

20/20 Biolabs, Inc. (AIDX) recorded an outflow of $1.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

20/20 Biolabs, Inc. (AIDX) had $4.1M in total assets as of fiscal year 2025, including both current and long-term assets.

20/20 Biolabs, Inc. (AIDX) invested $593K in research and development during fiscal year 2025.

20/20 Biolabs, Inc. (AIDX) had 10M shares outstanding as of fiscal year 2025.

20/20 Biolabs, Inc. (AIDX) had a current ratio of 0.60 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

20/20 Biolabs, Inc. (AIDX) had a return on assets of -90.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

20/20 Biolabs, Inc. (AIDX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $3.0M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

20/20 Biolabs, Inc. (AIDX) trades at 1.5x sales, its market capitalization divided by $2.0M revenue, FY2025. The market capitalization is $3.0M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, 20/20 Biolabs, Inc. (AIDX) held $1.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $1.9M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

20/20 Biolabs, Inc. (AIDX) has negative shareholder equity of -$19K as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

20/20 Biolabs, Inc. (AIDX) has an Altman Z-Score of -13.27, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

20/20 Biolabs, Inc. (AIDX) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

20/20 Biolabs, Inc. (AIDX) reported a net loss of $3.7M while operations used $1.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

20/20 Biolabs, Inc. (AIDX) reported an operating loss of $3.3M against $156K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

20/20 Biolabs, Inc. (AIDX) scores 34 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For 20/20 Biolabs, Inc. it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.